NASDAQ : CYCCP

Cyclacel Pharmaceuticals, Inc.

$5.05 USD

-$0.23 (-4.36%)

Volume
6.46K
Average Volume
5.72K
Market Capitalization
$11.31M
P/E Ratio
-9.19
Dividend Yield
11.88%
Price Target
Year High
$17.00
Year Low
$3.29
Day High
—
Day Low
—
Payout Ratio
-$0.04
Current Ratio
$7.06
Company Overview

NASDAQ

Sing Ee Wong

Biotechnology

Healthcare

CYCCP

12

US

USD

https://www.cyclacel.com

908 517 7330

23254L876

0001130166

Liquidity Metrics

0.00

7.06

5.87

4.19

-0.04

Sales & Valuation

$747K

7415.69

4.08

-1.85

-1.12

Profitability

-$6.45

-$3M

-196597.77%

-206622.95%

-69.56%

-39.64%

P/E Metrics

-9.19

0.13

0.13

Analyst Price Target & Rating

N/A

0/5

5 Analysts

%

Poll Results

About Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCCP) Stock

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing therapeutic solutions for cancer and various other proliferative disorders. At the forefront of its pipeline are several investigational therapies: Fadraciclib, a cyclin-dependent kinase (CDK) inhibitor, is currently undergoing Phase 1/2 clinical evaluation. It's being assessed as a monotherapy for solid tumors and in combination with venetoclax for managing relapsed or refractory chronic lymphocytic leukemia. Another promising candidate is CYC140, a polo-like kinase inhibitor, also progressing through Phase 1/2 trials for advanced leukemias and various solid tumor types. The pipeline further features Sapacitabine, an orally available prodrug of CNDAC and a novel nucleoside analog. This compoun ... d is in Phase 1/2 clinical investigation for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Additionally, seliciclib, another CDK inhibitor, is being explored in investigator-sponsored trials (ISTs), specifically in Phase 2 for Cushing's disease and Phase 1/2 for advanced rheumatoid arthritis. Underscoring its commitment to research, Cyclacel maintains a clinical collaboration with the University of Texas MD Anderson Cancer Center. This partnership aims to assess the safety and effectiveness of three of its compounds in patients suffering from various hematological malignancies, including chronic lymphocytic leukemia, acute myeloid leukemia, myelodysplastic syndromes, and other advanced forms of leukemia. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Frequently Asked Questions

What is the current Cyclacel Pharmaceuticals, Inc. (CYCCP) stock price?

Cyclacel Pharmaceuticals, Inc.(NASDAQ:CYCCP) stock price is $5.05 in the last trading session. During the trading session, CYCCP stock reached the peak price of $17 while $3.29 was the lowest point it dropped to. The percentage change in CYCCP stock occurred in the recent session was --4.36% while the dollar amount for the price change in CYCCP stock was -$0.23.

CYCCP's industry and sector of operation?

The NASDAQ listed CYCCP is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of CYCCP?

Brian Schwartz | Chief Medical Officer
Sing Ee Wong | Chairman, Chief Executive Officer & President
Grace Kim | Investor Relations Executive
Spiro George Rombotis | President
Gill Christie | Director of Human Resources

How many employees does CYCCP have?

Number of CYCCP employees currently stands at 12. CYCCP operates from 200 Connell Drive, Berkeley Heights, NJ 07922, US.

Link for CYCCP official website?

Official Website of CYCCP is: https://www.cyclacel.com

How do I contact CYCCP?

CYCCP could be contacted at phone #908 517 7330 and can also be accessed through its website. CYCCP operates from 200 Connell Drive, Berkeley Heights, NJ 07922, US.

How many shares of CYCCP are traded daily?

The average number of CYCCP shares traded daily for last 3 months was 5.72K.

What is the market cap of CYCCP currently?

The market value of CYCCP currently stands at $11.31M with its latest stock price at $5.05